Carreno, Beatriz M.
University of Pennsylvania
9 papers on CoChatORCID 0000-0002-8123-2035
Most cited papers
- Verified
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine
T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers
Cited by 5,294
- Verified
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 2,955
- Verified
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science
CAR-T cell therapy researchCRISPR and Genetic Engineering
Cited by 1,478
- Verified
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science
Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
Cited by 1,285
- Verified
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell
vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers
Cited by 538
- Verified
Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells
Wright, J. F., Guo, Y., Quazi, A., Luxenberg, D. P., Bennett, F., Ross, J. F., Qiu, Y., Whitters, M. J., Tomkinson, K. N., Dunussi-Joannopoulos, K., et al. (2007) · Journal of Biological Chemistry
Cytokine Signaling Pathways and InteractionsPsoriasis: Treatment and Pathogenesis
Cited by 319
- Verified
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications
Immunotherapy and Immune Responsesvaccines and immunoinformatics approaches
Cited by 113
- Verified
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Garfall, A. L., Cohen, A. D., Susanibar-Adaniya, S. P., Hwang, W.-T., Vogl, D. T., Waxman, A. J., Lacey, S. F., Gonzalez, V. E., Fraietta, J. A., Gupta, M., et al. (2023) · Blood Cancer Discovery
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 83
- Verified
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Linette, G. P., Bear, A. S., & Carreno, B. M. (2024) · Clinical Cancer Research
Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free